azomycin has been researched along with Bilirubinemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hui, AM; Li, K; Liu, Y; Lu, Z; Tan, Y; Wei, G; Yang, B | 1 |
| Andreeff, M; Badar, T; Benito, JM; Borthakur, G; Cortes, JE; Faderl, S; Handisides, DR; Harutyunyan, K; Jabbour, E; Kantarjian, HM; Konoplev, S; Konopleva, M; Kroll, S; Pearce, T; Richie, MA; Thomas, DA | 1 |
2 trial(s) available for azomycin and Bilirubinemia
| Article | Year |
|---|---|
Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study.
Topics: Adult; Area Under Curve; Asian People; China; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Humans; Hyperbilirubinemia; Male; Nitroimidazoles; Young Adult | 2022 |
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Topics: Adult; Aged; Bone Marrow; Esophagitis; Female; Humans; Hyperbilirubinemia; Hypoxia; Leukemia; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Nitroimidazoles; Phosphoramide Mustards; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prodrugs; Salvage Therapy; Stomatitis; Young Adult | 2016 |